Ulcerative proctitis: Challenges for clinical management

Journal of Gastroenterology and HepatologyEarly View Letter to the Editor Ulcerative proctitis: Challenges for clinical management B Caron, B Caron Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, FranceSearch for more papers by this authorL Peyrin-Biroulet, Corresponding Author L Peyrin-Biroulet [email protected] orcid.org/0000-0003-2536-6618 Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France Correspondence Prof Laurent Peyrin-Biroulet, MD, PhD, Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, 1 Allée du Morvan, 54511 Vandoeuvre-lès-Nancy, France. Email: [email protected]Search for more papers by this author B Caron, B Caron Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, FranceSearch for more papers by this authorL Peyrin-Biroulet, Corresponding Author L Peyrin-Biroulet [email protected] orcid.org/0000-0003-2536-6618 Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France Correspondence Prof Laurent Peyrin-Biroulet, MD, PhD, Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, 1 Allée du Morvan, 54511 Vandoeuvre-lès-Nancy, France. Email: [email protected]Search for more papers by this author First published: 11 May 2023 https://doi.org/10.1111/jgh.16216 Declaration of conflict of interest: B Caron has received lecture and/or consulting fees from AbbVie, Amgen, Celltrion, Ferring, Janssen, and Takeda. L Peyrin-Biroulet has received consulting fees from AbbVie, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Celltrion, CONNECT Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, HAC-Pharma, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Norgine, Novartis, OM Pharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Pfizer, Prometheus, Protagonist, Roche, Sandoz, Takeda, Theravance, Thermo Fisher, Tigenix, Tillots, Viatris, Vifor, Ysopia, and Abivax; grants from Takeda, Fresenius Kabi, and Celltrion; lecture fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Celltrion, Takeda, Pfizer, Sandoz, Biogen, MSD, Amgen, Vifor, Arena, Lilly, Gilead, Viatris, and Medac; and stock options from CTMA. Financial support: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Raja SS, Bryant RV, Costello SP, Barnett M, Schubert J, Rayner CK. Systematic review of therapies for refractory ulcerative proctitis. J Gastroenterol Hepatol n/a. https://doi.org/10.1111/jgh.16111 2Bouguen G, Roblin X, Bourreille A et al. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther 2010; 31: 1178– 1185. https://doi.org/10.1111/j.1365-2036.2010.04293.x 3Mallet AL, Bouguen G, Conroy G et al. Azathioprine for refractory ulcerative proctitis: a retrospective multicenter study. Dig Liver Dis 2017; 49: 280– 285. https://doi.org/10.1016/j.dld.2016.12.001 4Pineton de Chambrun G, Amiot A, Bouguen G et al. Efficacy of tumor necrosis factor antagonist treatment in patients with refractory ulcerative proctitis. Clin Gastroenterol Hepatol 2020; 18: 620– 627.e1. https://doi.org/10.1016/j.cgh.2019.05.060 5de Chambrun GP, Danese S, Peyrin-Biroulet L. Time to include patients with ulcerative proctitis in clinical trials. Lancet Gastroenterol Hepatol 2019; 4: 900– 902. https://doi.org/10.1016/S2468-1253(19)30341-3 6Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. Drug development for ulcerative proctitis: current concepts. Gut 2021; 70: 1203– 1209. https://doi.org/10.1136/gutjnl-2021-324108 7Caron B, Sandborn WJ, Panaccione R et al. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. J Crohns Colitis 2022; 16: 922– 930. https://doi.org/10.1093/ecco-jcc/jjab218 8Caron B, Abreu MT, Siegel CA et al. IOIBD recommendations for clinical trials in ulcerative proctitis: the PROCTRIAL consensus. Clin Gastroenterol Hepatol 2022; 20: 2619– 2627.e1. https://doi.org/10.1016/j.cgh.2022.02.032 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation